Noxilizer Appoints CFO, Transitions to Expanded Office and Lab as Rapid Growth Continues
Seasoned financial executive, David Chaskin brings 25 year’s experience to team dedicated to expanding NO2 sterilization market
(Baltimore, MD) –Â Noxilizer, Inc., the company behind the unique and superior, room temperature NO2-based sterilization technology for life science manufacturers and hospitals, announced today the appointment of Mr. David Chaskin as CFO.
Mr. Chaskin, the first of several planned hires to support Noxilizer’s expansion and will be responsible for all aspects of the company's finance and accounting. President and CEO, Larry Bruder said, “Noxilizer is poised for growth. We have a clear commercialization plan and David will be a key member of our leadership team in support of our plan and advancing NO2 sterilization in the global marketplace. David has a deep knowledge of finance, accounting, and operations and understands how to take organizations to the next level.”
Mr. Chaskin brings over 25 years of accounting and financial reporting experience in a variety of strategic and financial executive roles. Most recently, he served as CFO for Aritas Group, Inc., a financial holding company, and the Financial and Operations Principal for the US broker dealer subsidiary, Aritas Securities LLC. Mr. Chaskin joined Aritas Group, Inc. a few months after its initial product launch and helped it grow into a company that achieved tens of millions of dollars of revenue. Prior to Aritas, he held a variety of financial roles for large, publicly-traded companies including Chemical Bank, Guess? and TBA Entertainment, and lead financial positions with smaller, privately-held companies.
Of the opportunity, Mr. Chaskin notes “Noxilizer, Inc. has a solid financial position, and is bringing a superior offering to the sterilization marketplace. There is incredible opportunity as the commercial team articulates the advantages of NO2 sterilization and delivers on customer needs, to grow revenue and build shareholder value.” The only room temperature sterilization solution, NO2 sterilization is highly-compatible with a wide range of drug-device products, and provides a safer, simpler, more economical alternative for manufacturers.
Also in support of the increased commercial activities, Noxilizer recently relocated to a 16,000 square foot office and laboratory space at the University of Maryland BioPark.  “Our new lab space allows us to respond to a growing number of inquiries for feasibility studies, increasing demand for our contract sterilization services, and ramp up production of the RTS 360 Industrial NO2 Sterilizer,” says Bruder. Additionally, it provides Noxilizer growing room as we advance our hospital program.”
Noxilizer’s new headquarters is located at 800 West Baltimore Street, Suite 151 Baltimore, MD 21201.
About Noxilizer, Inc.:
Noxilizer has a unique and superior room temperature NO2-based sterilization technology that is revolutionizing two major sterilization markets — medical device/ pharmaceutical/biotechnology manufacturing and hospitals. In the manufacturing market, Noxilizer provides sterilization services for medical devices and drug/device combination products. Noxilizer sells the RTS 360 Industrial NO2 Sterilizer to companies who sterilize products in-house and also offers contract sterilization services. In hospitals, Noxilizer is developing a system especially for sensitive, high-tech equipment used in minimally-invasive surgical procedures. Noxilizer is headquartered in Baltimore, MD with offices in the US and Japan. Noxilizer, Inc. is privately held and was founded in 2004. For more information about Noxilizer, please visit: www.noxilizer.com.
Media Contact:
Angie Kearns
Brand Manager Noxilizer, Inc.
C (574) 304-1502
akearns@noxilizer.com
